Rocket Lab Corporation
RKLB
$59.10
+0.85%
Rocket Lab Corporation is a vertically integrated space company operating in the Aerospace & Defense industry, providing end-to-end mission services through its two reporting segments: Launch Services (the Electron small-lift rocket and the in-development medium-lift Neutron vehicle) and Space Systems (the Photon satellite platform, spacecraft components, and constellation manufacturing). The company has established itself as the dominant Western provider of dedicated small-launch services, a niche it has effectively consolidated while positioning Neutron as its bid to challenge SpaceX's Falcon 9 in the medium-lift market. The current investor narrative is dominated by two competing forces: the October 2026 disclosure that Neutron's debut has slipped to 2027 — which triggered a single-day drawdown of as much as 16% and a broader de-rating — against a backdrop of record contract bookings, a backlog reported near $2.36 billion, and the pending $8 billion acquisition of Iridium Communications that management argues could make the combined entity profitable and cash-flow positive by 2027. Bulls frame the sell-off as an overreaction to a schedule slip that does not impair the long-term launch cadence or the strategic value of the Iridium deal, while bears point to a valuation that still prices in flawless execution despite a widening cash burn and a launch timeline that has now slipped materially.…
RKLB
Rocket Lab Corporation
$59.10
Related headlines
Investment Opinion: Should I buy RKLB Today?
Rating: Hold, with a speculative-growth tilt. The core thesis is that Rocket Lab owns the Western small-launch niche and is building a second growth engine in Neutron and Iridium, but at 61.5x sales and a 914.9x forward PE the stock already discounts much of that success. The analyst consensus is 'buy' (mean 1.59 across 20 analysts) with an average target of $102.15, implying ~94% upside, but the low target of $64 is only ~22% above the current price, reflecting wide disagreement.
The supporting evidence is mixed but leans constructive on operations: revenue grew 62.0% YoY to $234.1M in Q2 2026, gross margin improved to 36.1% from 32.1% a year earlier, backlog stands near $2.36B, and the balance sheet is strong (current ratio 4.08, debt-to-equity 0.147). Against that, free cash flow is -$398.4M, net margin is -32.9%, and dilution is running at roughly 24.5% over five quarters. The valuation is the swing factor: 61.5x sales and 38.1x EV/sales are far above what the growth rate alone can justify without a clear path to profitability.
The biggest risks that could invalidate the thesis are a second Neutron delay, a dilutive or poorly integrated Iridium acquisition, and continued cash burn forcing another capital raise. This Hold would upgrade to Buy if Neutron reaches the pad on schedule and free cash flow trends toward breakeven, or if the stock de-rates to roughly 30-35x sales (around $30-35 per share) while the backlog holds. It would downgrade to Sell if Neutron slips beyond 2027 or if quarterly cash burn exceeds $150M without a financing plan. Verdict: overvalued relative to current fundamentals, but fairly valued relative to the option value of Neutron plus Iridium if both execute.
Sign up to view all
RKLB 12-Month Price Forecast
The forward view is balanced: Rocket Lab has genuine operating momentum in revenue growth, margin expansion, and backlog, but the valuation at 61.5x sales and a 914.9x forward PE already capitalizes a successful Neutron and Iridium outcome. The Neutron delay to 2027 and the -$398.4M free cash flow burn are the key swing factors, and the stock's 2.94 beta means the market will punish any further disappointment severely, as the -25.2% one-month decline shows. I would upgrade to bullish if Neutron reaches the pad on schedule and free cash flow trends toward breakeven, or if the stock de-rates to roughly 30-35x sales while the backlog holds. I would downgrade to bearish if Neutron slips beyond 2027 or if quarterly cash burn accelerates without a credible financing plan.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rocket Lab Corporation's 12-month outlook, with a consensus price target around $102.15 and implied upside of +72.8% versus the current price.
Average Target
$102.15
0 analysts
Implied Upside
+72.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$64 - $150
Analyst target range
Bulls vs Bears: RKLB Investment Factors
The bear case currently has stronger near-term evidence: the Neutron slip to 2027, a -$398.4M trailing free cash flow, and a 61.5x sales multiple have combined to drive a 25.2% one-month decline and a -42.2% YTD relative-strength gap versus the S&P 500. The bull case rests on genuinely impressive operating momentum — 62.0% revenue growth, gross margin up ~940bp in two years, a $2.36B backlog, and record contract bookings — plus a fortress balance sheet (current ratio 4.08, D/E 0.147) that buys time. The single most important tension is whether the $8B Iridium acquisition plus Neutron's 2027 debut can convert today's revenue growth into positive free cash flow before the valuation, at 61.5x sales, forces a further de-rating. If Iridium closes cleanly and management's 2027 cash-flow-positive target holds, the current 94% upside to the $102.15 average target is plausible; if either slips again, the multiple has far further to compress.
Bullish
- Revenue growth accelerating sharply: Q2 2026 revenue of $234.1M grew 61.99% year-over-year versus $144.5M in Q2 2025, and rose sequentially from $200.3M in Q1 2026. The top line has now compounded across four straight quarters ($155.1M → $179.7M → $200.3M → $234.1M), demonstrating that the Space Systems segment is scaling even before Neutron flies.
- Record backlog and contract wins: Backlog is reported near $2.36B, and the company just booked its largest-ever Electron contract in October 2026 — its second consecutive record. This contracted revenue provides multi-year visibility that is unusual for a company at this revenue scale and cushions the Neutron schedule slip.
- Gross margin structurally improving: Gross margin reached 36.13% in Q2 2026 versus 32.10% in Q2 2025 and 26.71% in Q3 2024, a roughly 940bp improvement over two years. The trajectory suggests operating leverage is emerging in Space Systems manufacturing as volumes rise.
- Fortress balance sheet, low leverage: Current ratio of 4.08 and debt-to-equity of just 0.147 mean the company can fund Neutron development and the Iridium integration without near-term solvency risk. Interest expense was only $0.58M in Q2 2026 against $16.5M of interest income, so the balance sheet is a net contributor to earnings.
Bearish
- Extreme valuation on every metric: At $52.60 the stock trades at 61.5x sales, 21.5x book, 38.1x EV/sales, and a forward PE of 914.9x. EV/EBITDA is negative (-234.4) because EBITDA is -$22.4M. These multiples price in flawless execution and leave no margin for error, as the recent 16% single-day drop demonstrated.
- Neutron delay pushes profitability out: The debut of Neutron has slipped to 2027, deferring the medium-lift revenue that underpins much of the growth thesis. With trailing free cash flow of -$398.4M and a net margin of -32.9%, the company remains dependent on external capital and the pending $8B Iridium deal to reach cash-flow breakeven.
- Persistent losses and cash burn: Q2 2026 net loss was $49.3M on $234.1M of revenue (net margin -21.0%), operating margin is -38.0%, and ROE is -11.5%. R&D alone consumed $82.4M in the quarter, up from $66.1M a year earlier, so the burn is widening as the company invests for growth.
- Severe underperformance and high beta: The stock is down 25.2% in one month, 34.0% over six months, and 30.8% YTD, versus the S&P 500's +11.45% YTD — a relative strength gap of -42.2% YTD. Beta of 2.94 means it amplifies market moves roughly threefold, and max drawdown has reached -66.16%.
RKLB Technical Analysis
Beta
2.94
2.94x market volatility
Max Drawdown
-66.2%
Largest decline past year
52-Week Range
$38-$151
Price range past year
Annual Return
-10.7%
Cumulative gain past year
| Period | RKLB Return | S&P 500 |
|---|---|---|
| 1m | -15.2% | +0.7% |
| 3m | -9.0% | +3.0% |
| 6m | -25.0% | +6.8% |
| 1y | -10.7% | +11.9% |
| ytd | -22.2% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RKLB Fundamental Analysis
Quarterly Revenue
$234066000.0B
2026-06
Revenue YoY Growth
+62.0%
YoY Comparison
Gross Margin
36.1%
Latest Quarter
Free Cash Flow
$-398353000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RKLB Overvalued?
PE
-188.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-234.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on cash consumption and the absence of profitability. Trailing free cash flow is -$398.4M, Q2 2026 net loss was $49.3M, and operating margin is -38.0%, while R&D spending rose to $82.4M from $66.1M a year earlier. Shares outstanding have grown from 505.6M (Q1 2025) to 629.7M (Q2 2026), a ~24.5% dilution that transfers value from existing holders, and the $8B Iridium acquisition will likely require additional debt or equity financing. Revenue is also concentrated in Space Systems and a small number of large government and commercial contracts, so a single program cancellation could materially dent the $2.36B backlog.
Market and competitive risks are dominated by valuation compression. At 61.5x sales, 21.5x book, and 38.1x EV/sales, RKLB trades at a steep premium to aerospace and defense peers, and a forward PE of 914.9x assumes an earnings inflection that has not yet appeared. Beta of 2.94 makes the stock highly sensitive to risk-off rotations, and the -42.2% YTD relative underperformance versus the S&P 500 shows that this sensitivity is already being realized. Competition is intensifying: SpaceX's Q3 earnings beat and explosive AI-driven revenue growth underscore how far ahead the incumbent is in medium-lift, while the Neutron delay to 2027 gives rivals more time to lock in launch contracts.
In a worst-case scenario, Neutron slips again into late 2027 or 2028, the Iridium deal closes on dilutive terms or fails to deliver the promised synergies, and a risk-off market compresses the sales multiple toward 20-25x. From $52.60, a retest of the 52-week low of $37.57 would represent roughly -29%, and the historical max drawdown of -66.16% shows how far the stock can fall in a genuine de-rating. Even the analyst low target of $64 is above the current price, so the downside is not fully reflected in Street models — an investor should be prepared for a -30% to -45% drawdown if execution disappoints.
FAQ
The most severe risk is execution on Neutron: the debut has slipped to 2027, and a second delay would undermine the medium-lift growth thesis that supports the 61.5x sales multiple. Second is financial risk from a -$398.4M trailing free cash flow burn and ~24.5% share dilution over five quarters, which could force another capital raise. Third is valuation compression: with beta at 2.94 and a -42.2% YTD relative-strength gap versus the S&P 500, a risk-off rotation could compress the multiple toward 20-25x sales. Fourth is integration and competitive risk from the $8B Iridium acquisition and SpaceX's continued dominance in medium-lift, which could lock in contracts during Rocket Lab's delay.
The 12-month forecast has three scenarios. The base case (55% probability) targets $64-$102, assuming Neutron flies in 2027 with modest delays, revenue grows toward the $2.7B consensus, and losses narrow. The bull case (20% probability) targets $102-$150, requiring an on-schedule Neutron launch, a clean Iridium close, and the 2027 cash-flow-positive target being met. The bear case (25% probability) targets $37-$64, reflecting a second Neutron slip, a dilutive Iridium deal, and multiple compression toward 20-25x sales. The base case is most likely, and its key assumption is that revenue grows roughly 60% YoY while gross margin holds in the mid-30s.
On traditional metrics RKLB is clearly overvalued: 61.5x sales, 21.5x book, 38.1x EV/sales, and a forward PE of 914.9x, with EV/EBITDA negative at -234.4 because EBITDA is -$22.4M. These multiples are far above aerospace and defense peers and imply the market expects revenue to compound at 60%+ for years while margins expand toward profitability. The stock has de-rated from a 52-week high of $151 to $52.60, down 30.8% YTD, so some of the premium has already compressed. The valuation is best described as pricing in flawless execution of Neutron and Iridium; it is fairly valued only if the 2027 profitability target is met, and overvalued if either program slips again.
From a risk/reward perspective, RKLB is a high-risk, high-reward proposition rather than a clean buy. The stock trades at $52.60 against an analyst average target of $102.15 (~94% upside) and a low target of $64 (~22% upside), so the Street sees meaningful appreciation potential. But the valuation is extreme at 61.5x sales and 914.9x forward PE, free cash flow is -$398.4M, and the Neutron delay to 2027 has already triggered a 25.2% one-month decline. The biggest downside risk is a retest of the 52-week low of $37.57, roughly -29% from here. It is a good buy only for risk-tolerant investors with a multi-year horizon who size the position small and can withstand a 2.94 beta and a -66.16% historical max drawdown.
RKLB is better suited to long-term holding than short-term trading, but only for risk-tolerant investors. The company is in a capital-intensive growth stage with negative earnings (EPS -$0.0054), no dividend (payout ratio 0), and a beta of 2.94 that produces violent short-term swings — the stock fell 25.2% in a single month and has a -66.16% historical max drawdown. Earnings visibility is limited because Neutron's 2027 debut and the Iridium integration are still ahead. A concrete minimum holding period of three to five years is appropriate to allow Neutron to reach cadence and the Iridium synergies to materialize; short-term traders should expect high volatility and use tight risk controls.